2025
Phoenix Sepsis Criteria in Critically Ill Children: Retrospective Validation Using a United States Nine-Center Dataset, 2012–2018
Sanchez-Pinto L, Daniels L, Atreya M, Faustino E, Farris R, Geva A, Khemani R, Rogerson C, Shah S, Weiss S, Bennett T. Phoenix Sepsis Criteria in Critically Ill Children: Retrospective Validation Using a United States Nine-Center Dataset, 2012–2018. Pediatric Critical Care Medicine 2025, 26: e155-e165. PMID: 39982153, PMCID: PMC11792981, DOI: 10.1097/pcc.0000000000003675.Peer-Reviewed Original ResearchConceptsInternational Pediatric Sepsis Consensus ConferenceInternational Pediatric Sepsis Consensus Conference criteriaPhoenix criteriaCritically ill childrenSepsis criteriaPICU admissionCohort of critically ill childrenOrgan dysfunction scoreIll childrenMulticenter cohort studyHigher risk of mortalityMortality of patientsAge groupsIn-hospital mortalityRisk of mortalitySeverity of illnessDiscrimination of mortalityBloodstream infectionsSuspected infectionMulticenter cohortSeptic shockSepsis scoreDysfunction scorePatient subgroupsRetrospective analysisRetrospective Visual and Quantitative Assessment of Burst Suppression With and Without Identical Bursts in Patients After Cardiac Arrest
Fong M, Pu K, Beekman R, Kim N, Nguyen C, Gilmore E, Hirsch L, Zaveri H. Retrospective Visual and Quantitative Assessment of Burst Suppression With and Without Identical Bursts in Patients After Cardiac Arrest. Neurocritical Care 2025, 1-11. PMID: 39900751, DOI: 10.1007/s12028-024-02208-7.Peer-Reviewed Original ResearchIdentical burstsBurst suppressionCardiac arrest survivorsInterburst intervalClinical featuresNeurological outcomeCardiac arrestArrest survivorsAssociated with poor neurological outcomeContinuous electroencephalogramCerebral Performance Category scoreAssociated with poor outcomesCardiac arrest patientsPoor neurological outcomePost-cardiac arrestPredictors of mortalityUS academic medical centersEEG backgroundPrognostic significanceArrest patientsClinical outcomesPoor outcomeRetrospective analysisAcademic medical centerUS cohortThe prognostic relevance of donor-specific antibodies in facial transplantation – A retrospective cohort study
Huelsboemer L, Hosseini H, Klimitz F, Diatta F, Boroumand S, O'Brien C, Parikh N, Stögner V, Formica R, Ko C, Azzi J, Draper E, Lian C, Murphy G, Pomahac B, Kauke-Navarro M. The prognostic relevance of donor-specific antibodies in facial transplantation – A retrospective cohort study. Journal Of Plastic Reconstructive & Aesthetic Surgery 2025, 103: 286-296. PMID: 40043533, DOI: 10.1016/j.bjps.2025.01.028.Peer-Reviewed Original ResearchDe novo donor-specific antibodiesDonor-specific antibodiesDonor-specific antibody positivityChronic rejectionC4d depositionGraft lossPrognostic relevanceRejection gradeGrades of acute cellular rejectionDonor-specific antibody statusOccurrence of chronic rejectionTime pointsFacial vascularized composite allotransplantationAcute rejection gradeAcute cellular rejectionTissue typing laboratoriesAcute rejection eventsRetrospective cohort studyTransplant-related outcomesFace transplant patientsVascularized composite allotransplantationCellular rejectionTransplant patientsC4d levelsRetrospective analysisTrends in Osteoporosis Drug Therapy Receipt Among Commercial and Medicare Advantage Enrollees in the United States, 2011-2022
Everhart A, Brito J, Clarke B, Herrin J, Karaca-Mandic P, Kennel K, Parimi N, Rosen C, Takagi M, McCoy R. Trends in Osteoporosis Drug Therapy Receipt Among Commercial and Medicare Advantage Enrollees in the United States, 2011-2022. The Journal Of Clinical Endocrinology & Metabolism 2025, dgae840. PMID: 39811927, DOI: 10.1210/clinem/dgae840.Peer-Reviewed Original ResearchOsteoporosis drug therapyFragility fracturesDocumented osteoporosisUndertreatment of osteoporosisMedicare Advantage enrolleesOptumLabs Data WarehouseUnderdiagnosis of osteoporosisHealth insuranceTherapy receiptPrimary outcomeRetrospective analysisDrug therapyOsteoporosisCuzick's testWomenMedicarePatientsUnderdiagnosisUnited StatesFilling rateSexLow rateAgeFractureYearsEfficacy and Safety of IV Thrombolysis for Acute Ischemic Stroke Patients With Moyamoya Disease
Chen H, Colasurdo M, Khunte M, Malhotra A, Gandhi D. Efficacy and Safety of IV Thrombolysis for Acute Ischemic Stroke Patients With Moyamoya Disease. Neurology 2025, 104: e210243. PMID: 39772663, DOI: 10.1212/wnl.0000000000210243.Peer-Reviewed Original ResearchConceptsAcute ischemic strokeTreated with IV thrombolysisIn-hospital mortalityMoyamoya disease patientsIV thrombolysisMoyamoya diseasePropensity score matchingIntracranial hemorrhageRisk factors of acute ischemic strokeSelf-careIschemic stroke patientsAcute ischemic stroke patientsStroke patientsTreating acute ischemic strokeNationwide Readmissions DatabaseRisk factorsRate of routine dischargeRoutine dischargeEfficacy outcomesAssociated with different ratesProspective studyBypass surgeryRetrospective analysisEstablished treatmentReadmissions Database
2024
The Relationship Between Quantitative Ischemia, Early Revascularization, and Major Adverse Cardiovascular Events A Multicenter Study
Miller R, Bednarski B, Cui Y, Calsavara V, Patel K, Rozanski A, Liang J, Builoff V, Acampa W, Bateman T, Di Carli M, Dorbala S, Einstein A, Fish M, Hauser M, Kaufmann P, Miller E, Ruddy T, Sharir T, Sinusas A, Dey D, Berman D, Slomka P. The Relationship Between Quantitative Ischemia, Early Revascularization, and Major Adverse Cardiovascular Events A Multicenter Study. JACC Advances 2024, 4: 101440. PMID: 39759439, PMCID: PMC11697767, DOI: 10.1016/j.jacadv.2024.101440.Peer-Reviewed Original ResearchMyocardial perfusion imagingEarly revascularizationMyocardial infarctionPerfusion imagingAssociated with reduced riskMedian follow-upImprove patient selectionAssociated with reduced deathSeverity of ischemiaMulticenter registryMale patientsPatient selectionRetrospective analysisFollow-upRandomized trialsRegistry sitesMyocardial ischemiaRevascularizationPatientsIschemiaSurvival analysisAuthors evaluated differencesPropensity scoreRegistryDeathReal-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer
Doshi J, Li P, Geng Z, Lei X, Pettit A, Armstrong K, Huntington S, Lin J. Real-World Analysis of Insurer Rejection Rates for Specialty Oral Anticancer Prescriptions in a Nationwide Sample of Patients with Blood Cancer. Blood 2024, 144: 786-786. DOI: 10.1182/blood-2024-203410.Peer-Reviewed Original ResearchInsurance typeBlood cancerMedicare patientsCommercial insuranceStep therapyFormulary coverageNationwide sample of patientsPrior authorizationTreatment plan changesDelayed treatment initiationMonths pre-indexOdds of rejectionLonger treatment durationLife-extending therapyReal-world studyOral anticancer medicationsSample of patientsBlood cancer patientsPatient ageClinical characteristicsTreatment initiationReal-world analysisBrand-nameRetrospective analysisPre-indexImpact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)
Yates S, Weiss J, Sneider A, Geramita E, Guru Murthy G, Badar T, Im A, Lin C, Cheng W, Winer E, Abaza Y, Litzow M, Atallah E, Swaroop A, Patel A, Shallis R. Impact of Time from Diagnosis to Treatment on Outcomes of Adults with AML Treated with HMA and Venetoclax: A US-Based, Multi-Center, Real-World, Retrospective Analysis from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). Blood 2024, 144: 447-447. DOI: 10.1182/blood-2024-207116.Peer-Reviewed Original ResearchDiagnosed AMLAcute myeloid leukemiaEuropean LeukemiaNetOverall survivalComplete responseECOG PSHypomethylating agentsSeverity of presentationMulti-centerPerformance statusRetrospective analysisFactors associated with improved OSTherapy-related acute myeloid leukemiaECOG PS of 2Initiation of induction therapyMultivariate analysisAssociated with worse OSNext generation sequencing panelIntermediate risk diseaseIncomplete count recoveryECOG performance statusDisease biologyNPM1 mutation statusUnivariate Cox modelPre-planned subgroup analysisClinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis
Guru Murthy G, Ball S, Feld J, Abboud R, Haddadin M, Patel S, Kishtagari A, Hawkins H, Guerra V, Dworkin E, Tawfiq R, Dulak D, Feng A, Cotte C, Cohen-Nowak A, Shukla A, Balasubramanian S, Winer E, Foucar C, Abaza Y, Shallis R, Lin C, Badar T, Patel A, Im A, Szabo A, Atallah E. Clinical Utilization and Outcomes of Hypomethylating Agents and Venetoclax in Patients with Myelodysplastic Syndrome - a Multicenter Retrospective Analysis. Blood 2024, 144: 3206-3206. DOI: 10.1182/blood-2024-211623.Peer-Reviewed Original ResearchHMA monotherapyTumor lysis syndromePhase 3 randomized clinical trialEvent free survivalHypomethylating agentsMulticenter retrospective analysisMyelodysplastic syndromeAdverse eventsUS academic medical centersClinical trialsUpfront settingFree survivalOverall survivalClinical outcomesRetrospective analysisClinical management of myelodysplastic syndromesIncidence of tumor lysis syndromeAcademic medical centerManagement of myelodysplastic syndromesAllogeneic stem cell transplantationSingle arm clinical trialResponse rateOutpatient settingStem cell transplantationMedical CenterContinuous Adductor Canal Block Compared to Epidural Anesthesia for Total Knee Arthroplasty
Freedman I, Mercier M, Galivanche A, Sandhu M, Hocevar M, Moore H, Grauer J, Rubin L, Li J. Continuous Adductor Canal Block Compared to Epidural Anesthesia for Total Knee Arthroplasty. Journal Of Pain Research 2024, 17: 3729-3740. PMID: 39559456, PMCID: PMC11572497, DOI: 10.2147/jpr.s462079.Peer-Reviewed Original ResearchContinuous adductor canal blockAdductor canal blockEpidural analgesiaEA patientsNon-home dischargeCanal blockMultivariate analysisIncidence of postoperative adverse eventsPostoperative adverse eventsMorphine equivalentsEpidural anesthesiaAdverse eventsRetrospective analysisHospital lengthProlonged LOSLevel IIIPatientsSteroidsTotal knee arthroplastyAdjuvantTKA patientsLogistic regressionDischarge dispositionAnalgesiaKnee arthroplastyTrends in Soft Palate Surgery and Reimbursements for Obstructive Sleep Apnea Among the Medicare Population
Torabi S, Frank M, Patel R, Manes R, Kuan E, Trask D. Trends in Soft Palate Surgery and Reimbursements for Obstructive Sleep Apnea Among the Medicare Population. Annals Of Otology Rhinology & Laryngology 2024, 134: 49-57. PMID: 39445448, DOI: 10.1177/00034894241288435.Peer-Reviewed Original ResearchPost‐exchange neutrophil count, but not post‐hematocrit, predicts endogenous erythropoiesis in patients with sickle cell disease undergoing chronic red cell exchange
Yurtsever N, Tong N, Geetha S, Nandi V, Shi P. Post‐exchange neutrophil count, but not post‐hematocrit, predicts endogenous erythropoiesis in patients with sickle cell disease undergoing chronic red cell exchange. Transfusion 2024, 64: 2270-2278. PMID: 39404130, DOI: 10.1111/trf.18044.Peer-Reviewed Original ResearchConceptsRed cell exchangeSickle cell diseaseChronic red cell exchangeCell exchangeSickle cell disease morbidityEndogenous erythropoiesisNeutrophil countCell diseaseAbsolute reticulocyte countPost-procedural parametersWhite cell countWhite blood cellsChronic transfusionPre-HCTSustained suppressionReticulocyte countRetrospective analysisWhite cell depletionMale genderCell depletionCell countIsovolemic hemodilutionReticulocytosisBlood cellsPatientsPacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival
Ajufo H, Bewersdorf J, Harrison C, Palandri F, Mascarenhas J, Palmer J, Gerds A, Kiladjian J, Buckley S, Derkach A, Roman‐Torres K, Rampal R. Pacritinib Response Is Associated With Overall Survival in Myelofibrosis: PERSIST‐2 Landmark Analysis of Survival. European Journal Of Haematology 2024, 114: 238-247. PMID: 39400386, PMCID: PMC11707811, DOI: 10.1111/ejh.14321.Peer-Reviewed Original ResearchSpleen volume reductionOverall survivalOS benefitNon-respondersAssociated with improved OSPatients treated with ruxolitinibAssociated with overall survivalAssociated with significant OS benefitImproved overall survivalSignificant OS benefitPERSIST-2Analysis of survivalUnique survival advantagesInhibitor of Janus kinaseJanus kinaseOS curvesRetrospective analysisSurvival advantageMyelofibrosisPacritinibPatientsRuxolitinibPlateletThrombocytopeniaVolume reductionPrognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction
Park H, Lee N, Hwang C, Cho S, Choi G, Cho J, Yoon H, Kim K, Ahn Y. Prognosis After Withdrawal of Cardioprotective Therapy in Patients With Improved Cancer Therapeutics–Related Cardiac Dysfunction. JACC CardioOncology 2024, 6: 699-710. PMID: 39479323, PMCID: PMC11522502, DOI: 10.1016/j.jaccao.2024.07.018.Peer-Reviewed Original ResearchCancer therapeutics-related cardiac dysfunctionLeft ventricular ejection fractionBaseline left ventricular ejection fractionCardioprotective therapiesCardiac dysfunctionClinical outcomesSingle-center prospective cohort studyMedian follow-up durationVentricular ejection fractionFollow-up durationLong-term prognosisProspective cohort studyEjection fractionEchocardiographic changesHeart failureRetrospective analysisClinical eventsCohort studyPatientsPrognosisDiagnosisTherapyDysfunctionWithdrawalBaselineMDS-772 Time Toxicity for Patients Receiving Oral Versus Parenteral Hypomethylating Agents for Myelodysplastic Syndromes/Neoplasms
Zeidan A, Olopoenia A, Costantino H, Modi K, Salimi T, Washington T, Krenitsky J, Epstein R. MDS-772 Time Toxicity for Patients Receiving Oral Versus Parenteral Hypomethylating Agents for Myelodysplastic Syndromes/Neoplasms. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s406. DOI: 10.1016/s2152-2650(24)01382-x.Peer-Reviewed Original ResearchHMA therapyRetrospective analysis of adult patientsAnalysis of adult patientsRoute of administrationMedian life expectancyPropensity score matchingHypomethylating agentsMDS treatmentBurden of treatmentAdult patientsPatient cohortInfusion dayParenteral treatmentMatched cohortResults PatientsRetrospective analysisOlder patientsEmergency room visitsCancer therapyHMA treatmentParenteral administrationTherapyPatientsOutpatient settingScore matchingAnalysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival
Pereslete A, Hughes M, Martin A, Files J, Nguyen K, Buckley L, Patel A, Moore A, Winer E, Dillon D, Li T, Tolaney S, Lin N, Sammons S. Analysis of HER2 expression changes from breast primary to brain metastases and the impact of HER2-low expression on overall survival. Neuro-Oncology 2024, 27: 184-194. PMID: 39211994, PMCID: PMC11726339, DOI: 10.1093/neuonc/noae163.Peer-Reviewed Original ResearchHER2-low expressionHER2-lowMetastatic breast cancerHER2-positiveHER2 expressionHER2-0Primary tumorBrain metastasesEstrogen receptorBreast cancerHER2-positive primary tumorsASCO-CAP guidelinesNCI-designated centersMultivariate survival analysisCox proportional hazards modelsAntibody-drug conjugatesProportional hazards modelActive antibody-drug conjugateASCO-CAPHER2 gainHER2 statusInferior survivalOverall survivalIntracranial activityRetrospective analysisPrevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis
Muradashvili T, Yu M, Browning S, Bar N, Gorshein E, Parker T, Neparidze N. Prevalence of metabolic comorbidities and viral co-infections in monoclonal gammopathy: a retrospective analysis. Leukemia 2024, 38: 2281-2283. PMID: 39164408, DOI: 10.1038/s41375-024-02380-x.Peer-Reviewed Original ResearchThe protein disulfide isomerase A3 and osteopontin axis promotes influenza‐induced lung remodelling
Kumar A, Mark Z, Carbajal M, DeLima D, Chamberlain N, Walzer J, Ruban M, Chandrasekaran R, Daphtary N, Aliyeva M, Poynter M, Janssen‐Heininger Y, Bates J, Alcorn J, Britto C, Dela Cruz C, Jegga A, Anathy V. The protein disulfide isomerase A3 and osteopontin axis promotes influenza‐induced lung remodelling. British Journal Of Pharmacology 2024, 181: 4610-4627. PMID: 39118388, DOI: 10.1111/bph.16511.Peer-Reviewed Original ResearchProtein disulfide isomerase A3Secreted phosphoprotein 1Lung fibrosisLung remodelingFibrotic remodelingViral infectionAssociated with pulmonary fibrosisInfluenza-infected patientsMacrophage colony-stimulating factorFibrotic lung remodelingSPP1 expressionRespiratory viral infectionsImproved oxygen saturationColony-stimulating factorLung fibrotic remodelingDebilitating clinical sequelaeIAV infectionFibrotic sequelaeClinical sequelaeTherapeutic optionsPulmonary fibrosisRetrospective analysisNeutralizing antibodiesCell culture modelHealthy controlsLetter in Reply to Comment on: Gynecomastia Surgery in 4996 Male Patients Over 14 Years: A Retrospective Analysis of Surgical Trends, Predictive Risk Factors, and Short-Term Outcomes
Kauke-Navarro M, Klimitz F, Pomahac B. Letter in Reply to Comment on: Gynecomastia Surgery in 4996 Male Patients Over 14 Years: A Retrospective Analysis of Surgical Trends, Predictive Risk Factors, and Short-Term Outcomes. Aesthetic Plastic Surgery 2024, 48: 4653-4655. PMID: 39085527, DOI: 10.1007/s00266-024-04285-7.Peer-Reviewed Original ResearchAbbreviated MRI in the evaluation of dizziness: report turnaround times and impact on length of stay compared to CT, CTA, and conventional MRI
Tu L, Tegtmeyer K, de Oliveira Santo I, Venkatesh A, Forman H, Mahajan A, Melnick E. Abbreviated MRI in the evaluation of dizziness: report turnaround times and impact on length of stay compared to CT, CTA, and conventional MRI. Emergency Radiology 2024, 31: 705-711. PMID: 39034381, DOI: 10.1007/s10140-024-02273-7.Peer-Reviewed Original ResearchLength of stayEvaluation of dizzinessAbbreviated MRIConventional MRIMRI protocolEmergency departmentNon-contrast CT headConventional MRI protocolHead and neckPosterior circulation strokeAnalysis of length of stayTurnaround timeED length of stayCT headNo significant differenceAcute dizzinessCirculation strokeRetrospective analysisDizzinessAcute settingAssociated with greater impactMRI studiesImaging modalitiesMRIPatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply